NYRequirements - Blog
Skin cancer is the most common, deadly form of cancer in the United States, but a study published in the Journal of Clinical Oncology says a modified version of herpes may be viable answer.
The treatment, T-VEC, is a genetically engineered version of herpes simplex virus type-1 that is injected into melanoma cancers.
Kevin Harrington, a professor of Biological Cancer Therapies at the Institute of Cancer Research in London, led the UK research team in the T-VEC study.
He found that the treatment not only killed cancer cells, but it stopped tumors from growing and helped strengthen the immune system against future cells.
Compared to chemotherapy, which can cause a number of side eff